Literature DB >> 27135849

[Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].

Marcelo Chaves1, Mariela Bettini, Sebastián Marciano, Soledad Sáez, Edgardo Cristiano, Marcelo Rugiero.   

Abstract

Transthyretin-related familial amyloid polyneuropathy (TTR-FAP) is a hereditary disease with variable geographical distribution. The aim of this study was to present our experience with TTR-FAP patients. We retrospectively analyzed nine cases belonging to different families. Diagnostic criteria were based on the combination of compatible clinical picture, histopathological findings and genetic confirmation. Five cases showed the classic presentation and other 4 the late onset variant. The p.Val30Met mutation in the TTR gene was found in 6 cases and p.Ala36Pro, p.Thr60Ala and p.Tyr114Cys in the remaining 3, respectively. The median age of symptom onset was 35 years (26-60 range). Mean time to diagnosis was 4.2 ± 1.5 years. Our patient series showed the heterogeneity in clinical presentation of TTR-FAP in a non-endemic region of South America.

Entities:  

Keywords:  Argentina; amyloid; familial amyloid polyneuropathy; transthyretin

Mesh:

Substances:

Year:  2016        PMID: 27135849

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  2 in total

1.  Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.

Authors:  Eve Piekarski; Renata Chequer; Vincent Algalarrondo; Ludivine Eliahou; Besma Mahida; Jonathan Vigne; David Adams; Michel S Slama; Dominique Le Guludec; Francois Rouzet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-06       Impact factor: 9.236

2.  Epidemiology of variant transthyretin amyloidosis at a reference center in Argentina.

Authors:  Maria S Saez; Maria A Aguirre; Diego Pérez de Arenaza; Patricia Sorroche; Elsa Nucifora; Maria L Posadas Martinez
Journal:  Mol Genet Genomic Med       Date:  2021-10-20       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.